Pharmaceutical intelligence for Ambros Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalAugust 15, 2026

Ambros Therapeutics initiates Phase 3 trial of AMBTX-01 for CRPS Type 1

Ambros Therapeutics has launched Phase 3 clinical trial evaluating AMBTX-01 (neridronate) for the treatment of Complex Regional Pain Syndrome Type 1.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalAugust 15, 2026

Ambros Therapeutics initiates Phase 3 trial of AMBTX-01 for CRPS Type 1

Ambros Therapeutics has launched Phase 3 clinical trial evaluating AMBTX-01 (neridronate) for the treatment of Complex Regional Pain Syndrome Type 1.

Competitive activity

No signals indexed for this entity yet.

Assets

AMBTX-01 →

Therapeutic areas

Neurology →

Pain Management →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.